Our analysis of the publicly available databases indicated that mutation JAK2 V617F was found in 6% of blasts from AML patients, and that expressions of FGFR1 and JAK3 were significantly higher in AML patients than in healthy people (Figure S1 and Figure 1). The gene discussed is JAK2; the disease is acute myeloid leukemia.